证券日报网讯 8月11日晚间，南微医学发布公告称，公司第四届监事会第八次会议审议通过了《关于公 司的议案》等多项议案。 （文章来源：证券日报） ...

Business Performance - Luxshare Technology plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - China Shipbuilding Industry Corporation will suspend trading from August 13 until delisting [1] - Hikvision's chairman proposed a mid-term dividend of 4 yuan per 10 shares (including tax) for 2025 [1] - North Medical's subsidiary has essentially halted its main business since June [1] - Shenzhen Huangting Plaza will be judicially auctioned with a starting price of 3.053 billion yuan [1] - ST Suwu's controlling subsidiary has initiated arbitration against Regen Biotech for default, which has been accepted [1] - ST Yigou plans to pay 220 million yuan to reach a debt settlement agreement with Carrefour [1] - Shanghai Jianke's director is under disciplinary review and investigation [1] Mergers and Acquisitions - Xincheng Technology has terminated the acquisition of 96.96% equity in Tianyi Enhua [1] - Guangku Technology intends to purchase 100% equity in Suzhou Anjie Xun Optoelectronics, with resumption of trading on the 12th [1] - ST Biology plans to acquire 51% equity in Huize Pharmaceutical, expected to constitute a major asset restructuring [1] - Dongfang Guoxin aims to gain control of Shituo Cloud to deepen its layout in the intelligent computing power sector [1] - Jinding Investment intends to control Nanjing Shenyuan, entering a key segment of the robotics industry chain [1] - Huangshanghuang plans to acquire 51% equity in Lixing Food for 495 million yuan [1] Financial Performance - Xianggang Technology reported a net profit of 78.32 million yuan in the first half, a year-on-year increase of 432.14% [1] - Yonghe Co. reported a net profit of 271 million yuan in the first half, a year-on-year increase of 140.82% [1] - Fuda Co. reported a net profit of 146 million yuan in the first half, a year-on-year increase of 98.77% [1] - Desay SV reported a net profit of 1.223 billion yuan in the first half, a year-on-year increase of 45.82% [1] - Dier Laser reported a net profit of 327 million yuan in the first half, a year-on-year increase of 38.37% [1] - Rijiu Optoelectronics reported a net profit of 45.61 million yuan in the first half, a year-on-year increase of 37.87% [1] - Wolong Electric Drive reported a net profit of 537 million yuan in the first half, a year-on-year increase of 36.76% [1] - Satellite Chemical reported a net profit of 2.744 billion yuan in the first half, a year-on-year increase of 33.44% [1] Other Financial Results - High Stakes Mining reported a net profit of 69.2 million yuan in the first half, a year-on-year increase of 25.7% [2] - Yingliu Co. reported a net profit of 188 million yuan in the first half, a year-on-year increase of 23.91% [2] - Nanwei Medical reported a year-on-year net profit increase of 17.04% and plans to distribute a dividend of 5 yuan per 10 shares (including tax) [2] - Zhejiang Huaye reported a year-on-year net profit increase of 6.66% and plans to distribute a dividend of 4 yuan per 10 shares (including tax) [2] - New Strong Union reported a net profit of 400 million yuan in the first half, returning to profitability [2] - Aobi Zhongguang reported a net profit of 60.19 million yuan in the first half, returning to profitability [2] - Action Education reported a year-on-year net profit decrease of 3.51% and plans to distribute a dividend of 10 yuan per 10 shares (including tax) [2] - Wanhu Chemical reported a net profit of 6.123 billion yuan in the first half, a year-on-year decrease of 25.10% [2] - New World reported a net profit of 78.03 million yuan in the first half, a year-on-year decrease of 30.01% [2] - Huafeng Chemical reported a net profit of 983 million yuan in the first half, a year-on-year decrease of 35.23% [2] - Hefo China reported a consolidated revenue of 425 million yuan in the first seven months, a year-on-year decrease of 22.66%, with a narrowing decline [2] - Shengnong Development reported a sales revenue of 2.129 billion yuan in July, a year-on-year increase of 22.02% [2] - Xiamen Airport reported a passenger throughput of 2.6248 million in July, a year-on-year increase of 8.58% [2]

| 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派5元（含税） | 0.93 | 0.76 | | 2024.12.31 | 10派10元（含税） | 1.87 | 1.44 | | 2024.06.30 | 10派5元（含税） | 0.94 | 0.71 | | 2023.12.31 | 10派10元（含税） | 1.87 | 1.19 | | 2022.12.31 | 10派5.5元（含税） | 1.03 | 0.56 | | 2021.12.31 | 10转增4派7.5元（含税） | 1.00 | 0.32 | | 2020.12.31 | 10派6元（含税） | 0.80 | 0.31 | | 2019.12.31 | 10派10元（含税） | 1.33 | 0.72 | 证券时报·数据宝统计显示，公司今日公布了半年报，共实现营业收入15.65亿元，同比增长17.36%，实 现净利润3.63亿元，同比增长17.04%，基本每股收益为1.94元。 8月11日南微医学发布2025半年度分配预案，拟 ...

北京商报讯（记者 丁宁）8月11日晚间，南微医学（688029）发布2025年半年报显示，2025年上半年， 公司实现营业收入15.65亿元，较上年同期增长17.36%；归属净利润3.63亿元，同比增长17.04%。 此外，公司拟向全体股东每10股派发现金红利5元（含税）。 ...

Core Viewpoint - Nanwei Medical's stock price closed at 92.39 yuan, up 9.34%, with a rolling PE ratio of 30.41, marking a new low in 387 days, and a total market capitalization of 17.355 billion yuan [1] Group 1: Company Performance - For the first half of 2025, Nanwei Medical reported revenue of 1.565 billion yuan, a year-on-year increase of 17.36%, and a net profit of 363 million yuan, also up 17.04%, with a gross profit margin of 64.89% [1] - The company specializes in the research, manufacturing, and sales of minimally invasive medical devices, with key products including endoscopic diagnostic instruments, microwave/radiofrequency ablation equipment and consumables, and disposable endoscopes [1] Group 2: Shareholder Information - As of June 30, 2025, Nanwei Medical had 12,345 shareholders, a decrease of 968 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 3: Industry Comparison - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Nanwei Medical at the 58th position in the industry ranking [1][2] - The static PE ratio for Nanwei Medical is 31.37, and the price-to-book ratio is 4.31 [2]

2025年上半年公司营业收入15.65亿元，较上年同期增长17.36%，收入的增长使得公司归属于上市公司 股东的净利润增长17.04%。 智通财经APP讯，南微医学(688029.SH)披露2025年半年度报告，报告期公司实现营收15.65亿元，同比 增长17.36%;归属于上市公司股东的净利润3.63亿元，同比增长17.04%;扣非净利润3.64亿元，同比增长 18.90%;基本每股收益1.94元。公司拟向全体股东每10股派发现金红利5.00元(含税)。 ...

Core Insights - Company reported a revenue of 1.565 billion yuan for the first half of 2025, a year-on-year increase of 17.36%, and a net profit of 363 million yuan, up 17.04% from the previous year [1] - The proportion of overseas revenue has increased to 58% of total income, indicating a strong global market presence [1] Group 1: Market Growth and Trends - The endoscopic market is experiencing rapid growth due to advancements in endoscopic surgery and related technologies, leading to increased demand for endoscopic instruments and consumables [1] - The global digestive endoscopy market was valued at $9.2 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 5.3%, reaching $13.1 billion by 2028 [1] - The global endoscopic diagnostic and therapeutic device market is projected to reach $7 billion by 2025, with an overall growth rate of 6% [1] Group 2: Company Innovations and R&D - Company has a deep understanding of the development trends in minimally invasive technology and clinical needs, having developed nearly 30 core technologies across six major areas of endoscopic diagnosis and treatment [2] - R&D investment for the first half of 2025 was 88.28 million yuan, accounting for 5.64% of revenue, focusing on innovation-driven growth [2] - New innovative products, including the three-arm clamp, have received market approval, and several projects are in the registration submission phase [2] Group 3: Global Expansion and Sustainability - Company has emphasized global expansion, with overseas revenue and profits showing significant growth, up 45% year-on-year [3] - The acquisition of 51% of Spanish company Creo Medical S.L.U. in February marks a significant step in expanding into the European market, with integration progressing smoothly [3] - The construction and operational preparation of the manufacturing center in Thailand is on track to commence production by the end of the year, enhancing the global supply chain [3]

南微医学（SH 688029，收盘价：92.39元）8月11日晚间发布半年度业绩报告称，2025年上半年营业收 入约15.65亿元，同比增加17.36%；归属于上市公司股东的净利润约3.63亿元，同比增加17.04%；基本 每股收益1.94元，同比增加16.87%。 （文章来源：每日经济新闻） ...

南微医学科技股份有限公司 2025年度"提质增效重回报"专项行动方案半年度评估报告 为践行以投资者为本的上市公司发展理念，维护公司全体股东利益，基于 对公司未来发展前景及价值的认可，推动南微医学科技股份有限公司（以下简 称"公司"或"南微"）持续优化经营、规范治理和积极回报投资者，大力提 高上市公司质量，助力信心提振、资本市场稳定和经济高质量发展，公司制定 并于2025年4月29日披露了《2024年度"提质增效重回报"专项行动方案评估 报告暨2025年度"提质增效重回报"行动方案》（以下简称"行动方案"）。 2025年上半年，行动方案主要举措的落实进展及成效情况具体如下： 一、强化发展韧性，进一步提升经营发展质量 报告期内，面对不确定性因素影响，公司紧密围绕战略目标和年度任务， 持续提高管理效率和经营利润率，努力提升经营业绩。 （1）2025年上半年，公司实现营收15.65亿元，较上年同期增长17.36%； 归母净利润3.63亿元，同比增长17.04%。从地区情况看，亚太区域营收8.08亿 元（其中亚太海外营收1.28亿元，康友营收1.34亿元），同比减少1.7%；美洲 区域营收3.41亿元，同比增长21.7 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《上海证券交易 所科创板上市公司自律监管指引第1号--规范运作》和《上海证券交易所科创板股 票上市规则》等相关规定，南微医学科技股份有限公司（以下简称"公司"）董事 会编制了2025年半年度（以下简称"报告期"）募集资金存放与实际使用情况专项 报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 根据中国证监会于2019年7月2日出具的《关于同意南京微创医学科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2019]1178号），公司获准向社会首 次公开发行股票3,334万股，每股发行价格为52.45元，本次发行募集资金总额人民 币1,748,683,000.00元，实际募集资金净额为人民币1,592,776,643.40元。中天运 会计师事务所（特殊普通合伙）于2019年7月17日对本次发行的资金到位情况进行 了审验，并出具了中天运[2019]验字第90038号验资报告。 证券代码：68802 ...